Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

ROP-ET: a Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2B in Essential Thrombocythemia Patients with Limited Treatment Options

Jean-Jacques Kiladjian,Francisca Ferrer Marin,Haifa Kathrin Al-Ali,Alberto Alvarez-Larrán,Eloise Beggiato,Maria Bieniaszewska,Massimo Breccia,Veronika Buxhofer-Ausch,Olga Cerna,Ana-Manuela Crisan,Catalin Doru Danaila,Valerio De Stefano,Konstanze Döhner,Victoria Empson,Joanna Gora-Tybor,Martin Griesshammer,Sebastian Grosicki,Paola Guglielmelli,Valentin García-Gutierrez,Florian H. Heidel,Arpád Illés,Ciprian Tomuleasa,Chloe James,Steffen Koschmieder,Maria-Theresa Krauth,Kurt Krejcy,Mihaela-Cornelia Lazaroiu,Jiri Mayer,Zsolt György Nagy,Franck-Emmanuel Nicolini,Francesca Palandri,Vassiliki Pappa,Andreas Johannes Reiter,Tomasz Sacha, Stefanie Schlager,Stefan Schmidt,Evangelos Terpos,Martin Unger,Albert Wölfler,Blanca Xicoy Cirici,Christoph Klade

Annals of Hematology（2024）

Cited 1|Views43
Key words
Myeloproliferative neoplasms (MPNs),Essential thrombocythemia (ET),Ropeginterferon alfa-2b,ROP-ET,Phase III,Disease modification
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined